For the quarter ending 2026-03-31, TELA had -$11,304K decrease in cash & cash equivalents over the period. -$11,289K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -12,273 | -9,041 | -8,603 | -21,187 |
| Depreciation expense | 169 | 130 | 153 | 347 |
| Noncash interest expense | 238 | 159 | 110 | 260 |
| Deferred income tax expense | - | - | 0 | 85 |
| Noncash loss on extinguishment of debt | - | 888 | - | - |
| Amortization of intangible assets | 95 | 95 | 95 | 190 |
| Net changes in operating lease rou assets and liabilities | 21 | 21 | -375 | 52 |
| Inventory excess and obsolescence charge | 935 | 818 | 632 | 910 |
| Stock-based compensation expense | 816 | 812 | 955 | 2,029 |
| Income tax expense | 60 | 230 | - | - |
| Loss on disposal of fixed assets | -18 | - | - | - |
| Accounts receivable, net | -593 | -932 | 107 | 935 |
| Inventory | 2,158 | 275 | 838 | -610 |
| Prepaid expenses and other current and long-term assets | -231 | 153 | -272 | -14 |
| Accounts payable | 1,593 | -63 | 652 | -448 |
| Accrued expenses and other current and long-term liabilities | -1,498 | 663 | 633 | 464 |
| Foreign currency transaction loss | -32 | -41 | 48 | -83 |
| Net cash used in operating activities | -11,170 | -4,870 | -5,719 | -17,630 |
| Purchase of property and equipment | 119 | 91 | 211 | 146 |
| Proceeds from the sale of product line | 309 | 283 | 523 | 488 |
| Net cash provided by investing activities | 190 | 192 | 312 | 342 |
| Proceeds from sale of common stock and pre-funded warrants, net | - | 11,823 | - | - |
| Proceeds from issuance of long-term debt and warrants | - | 60,000 | - | - |
| Repayment of long-term debt | - | 42,420 | - | - |
| Payment of debt financing costs | - | 3,554 | - | - |
| Payment of accrued offering costs | 247 | - | - | - |
| Proceeds from exercise of stock options | - | 0 | 0 | 1 |
| Vesting of restricted stock units | 1 | - | - | - |
| Payment of withholding taxes related to stock-based compensation to employees | 79 | 4 | 21 | 180 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 27 | 0 | 45 | 60 |
| Net cash used in financing activities | -298 | 25,845 | 24 | -119 |
| Effect of exchange rate on cash and cash equivalents | -26 | -35 | 104 | -286 |
| Net decrease in cash and cash equivalents and restricted cash | -11,304 | 21,132 | -5,279 | -17,693 |
| Cash and cash equivalents and restricted cash, beginning of period | 51,095 | 29,963 | 52,935 | - |
| Cash and cash equivalents and restricted cash, end of period | 39,791 | 51,095 | 29,963 | - |
TELA Bio, Inc. (TELA)
TELA Bio, Inc. (TELA)